Lyell CEO Lynn Seely at #BIO24 (Brian Benton Photography)
October 25, 2024 11:17 AM EDTUpdated 11:33 AM
Deals
Cell/Gene Tx

Lyell Im­munophar­ma to ac­quire Imm­PACT Bio, cut top pro­grams

Katherine Lewin

News Reporter

Lyell Im­munophar­ma is dis­con­tin­u­ing sev­er­al pro­grams and ac­quir­ing CAR-T biotech Imm­PACT Bio and its suite of clin­i­cal-stage can­di­dates for $30 mil­lion …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Pa­tient dies in Neu­ro­gene's Rett syn­drome study

Lil­ly's board un­der­goes more changes; Mer­ck strat­e­gy chief joins Roger Perl­mut­ter at Eikon

Sur­round­ed by AI bio gi­ants, tiny start­up Nabla Bio makes de no­vo an­ti­bod­ies look more like drugs 

Halozyme with­draws Evotec ac­qui­si­tion pro­pos­al af­ter biotech is 'un­will­ing to en­gage'

From vac­cines to psy­che­delics, five drug­mak­ers on what could change un­der a Trump ad­min­is­tra­tion

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times